BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30061950)

  • 1.
    Hachiman M; Yoshimitsu M; Ezinne C; Kuroki A; Kozako T; Arima N
    Oncol Lett; 2018 Jul; 16(1):1305-1311. PubMed ID: 30061950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells.
    Kinpara S; Kijiyama M; Takamori A; Hasegawa A; Sasada A; Masuda T; Tanaka Y; Utsunomiya A; Kannagi M
    Retrovirology; 2013 May; 10():52. PubMed ID: 23688327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?
    Nasr R; El Hajj H; Kfoury Y; de Thé H; Hermine O; Bazarbachi A
    Viruses; 2011 Jun; 3(6):750-69. PubMed ID: 21994752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation.
    Yuen CK; Chan CP; Fung SY; Wang PH; Wong WM; Tang HV; Yuen KS; Chan CP; Jin DY; Kok KH
    J Virol; 2016 Apr; 90(8):3902-3912. PubMed ID: 26819312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).
    Kchour G; Tarhini M; Kooshyar MM; El Hajj H; Wattel E; Mahmoudi M; Hatoum H; Rahimi H; Maleki M; Rafatpanah H; Rezaee SA; Yazdi MT; Shirdel A; de Thé H; Hermine O; Farid R; Bazarbachi A
    Blood; 2009 Jun; 113(26):6528-32. PubMed ID: 19411628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells.
    Bazarbachi A; El-Sabban ME; Nasr R; Quignon F; Awaraji C; Kersual J; Dianoux L; Zermati Y; Haidar JH; Hermine O; de Thé H
    Blood; 1999 Jan; 93(1):278-83. PubMed ID: 9864171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.
    Nasr R; Marçais A; Hermine O; Bazarbachi A
    Methods Mol Biol; 2017; 1582():197-216. PubMed ID: 28357672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma.
    Bazarbachi A; Nasr R; El-Sabban ME; Mahé A; Mahieux R; Gessain A; Darwiche N; Dbaibo G; Kersual J; Zermati Y; Dianoux L; Chelbi-Alix MK; de Thé H; Hermine O
    Leukemia; 2000 Apr; 14(4):716-21. PubMed ID: 10764160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
    Hermine O; Dombret H; Poupon J; Arnulf B; Lefrère F; Rousselot P; Damaj G; Delarue R; Fermand JP; Brouet JC; Degos L; Varet B; de Thé H; Bazarbachi A
    Hematol J; 2004; 5(2):130-4. PubMed ID: 15048063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells.
    Nasr R; Rosenwald A; El-Sabban ME; Arnulf B; Zalloua P; Lepelletier Y; Bex F; Hermine O; Staudt L; de Thé H; Bazarbachi A
    Blood; 2003 Jun; 101(11):4576-82. PubMed ID: 12560223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide (As
    Marçais A; Cook L; Witkover A; Asnafi V; Avettand-Fenoel V; Delarue R; Cheminant M; Sibon D; Frenzel L; de Thé H; Bangham CRM; Bazarbachi A; Hermine O; Suarez F
    Retrovirology; 2020 Mar; 17(1):5. PubMed ID: 32199462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives.
    Bazarbachi A; Hermine O
    Virus Res; 2001 Oct; 78(1-2):79-92. PubMed ID: 11520582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma.
    Hermine O; Allard I; Lévy V; Arnulf B; Gessain A; Bazarbachi A;
    Hematol J; 2002; 3(6):276-82. PubMed ID: 12522449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells.
    Darwiche N; El-Sabban M; Bazzi R; Nasr R; Al-Hashimi S; Hermine O; de Thé H; Bazarbachi A
    Hematol J; 2001; 2(2):127-35. PubMed ID: 11424005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.
    Kchour G; Rezaee R; Farid R; Ghantous A; Rafatpanah H; Tarhini M; Kooshyar MM; El Hajj H; Berry F; Mortada M; Nasser R; Shirdel A; Dassouki Z; Ezzedine M; Rahimi H; Ghavamzadeh A; de Thé H; Hermine O; Mahmoudi M; Bazarbachi A
    Retrovirology; 2013 Aug; 10():91. PubMed ID: 23962110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients.
    Bazarbachi A; Hermine O
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996; 13 Suppl 1():S186-90. PubMed ID: 8797722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.
    Bazarbachi A; Plumelle Y; Carlos Ramos J; Tortevoye P; Otrock Z; Taylor G; Gessain A; Harrington W; Panelatti G; Hermine O
    J Clin Oncol; 2010 Sep; 28(27):4177-83. PubMed ID: 20585095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis.
    Shafiee A; Seighali N; Taherzadeh-Ghahfarokhi N; Mardi S; Shojaeian S; Shadabi S; Hasani M; Haghi S; Mozhgani SH
    Virol J; 2023 Jun; 20(1):118. PubMed ID: 37287047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha.
    Mahieux R; Hermine O
    Leuk Lymphoma; 2005 Mar; 46(3):347-55. PubMed ID: 15621824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
    Dbaibo GS; Kfoury Y; Darwiche N; Panjarian S; Kozhaya L; Nasr R; Abdallah M; Hermine O; El-Sabban M; de Thé H; Bazarbachi A
    Haematologica; 2007 Jun; 92(6):753-62. PubMed ID: 17550847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.